Johannesen et al. conducted a study which revealed that in patients undergoing statin treatment, elevated levels of apolipoprotein B (apoB) and non-HDL cholesterol, rather than LDL cholesterol, are correlated with residual risk of all-cause mortality and myocardial infarction. Here, APOB is linked to myocardial infarction.